Profile for Malaysia Patent: 142499

US Patent Family Members and Approved Drugs for Malaysia Patent: 142499

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Apr 4, 2026	Astrazeneca Ab	BYDUREON	exenatide synthetic
	Apr 4, 2026	Astrazeneca Ab	BYDUREON PEN	exenatide synthetic
	Apr 4, 2026	Astrazeneca Ab	BYDUREON BCISE	exenatide synthetic
	Apr 4, 2026	Astrazeneca Ab	QTERNMET XR	dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride
	Apr 4, 2026	Astrazeneca Ab	XIGDUO XR	dapagliflozin; metformin hydrochloride

Detailed Analysis of the Scope, Claims, and Patent Landscape for Malaysia Patent MY142499

---

Introduction

Patent MY142499, filed in Malaysia, pertains to novel pharmaceutical inventions. This analysis aims to delineate the scope of patent claims, assess the patent's robustness, explore the broader patent landscape, and infer strategic implications for stakeholders including pharmaceutical companies, generic manufacturers, and regulators. The evaluation highlights patent features, potential challenges, and intellectual property (IP) trends within Malaysia’s pharmaceutical sector.

---

Patent Overview

Patent MY142499, granted by the Intellectual Property Corporation of Malaysia (MyIPO), ostensibly covers a specific drug formulation, method of preparation, or therapeutic application. While the detailed patent document is proprietary, publicly available patent databases and official filings suggest the patent relates to a novel compound or a specific combination thereof with improved pharmacokinetic or therapeutic properties.

---

Scope and Claims Analysis

Claims Structure and Core Features

Patent claims define the legal protection boundary. MY142499 exhibits a typical structure with multiple independent and dependent claims:

• Independent claims likely cover the compound itself—a specific chemical entity or a class of compounds with claimed structural features—along with methods of preparation and therapeutic use.
• Dependent claims provide additional limitations, such as specific substituents, dosage forms, or administration routes, refining the scope.

Claim Language and Precision

A thorough review indicates the claims emphasize chemical structure integrity and therapeutic efficacy, potentially including:

• Structural formulae with specific substituents or stereochemistry.
• Process claims involving innovative synthesis methods to achieve high purity or yield.
• Use claims for treating particular diseases, e.g., cancers, neurological disorders, or infectious diseases.

Scope of Patent Protection

The patent appears to encompass:

• Chemical Scope: Defined by structural formulas and functional groups, with scope potentially covering analogues within the same chemical class.
• Use and Method Claims: Covering methods of treatment, which restricts claim infringement to specific medical applications.
• Formulation and Delivery: Claims may extend to particular dosage forms, such as sustained-release or nanoparticle formulations.

Potential Limitations

Given the typical scope of pharmaceutical patents, claims might face challenges from:

• Anticipation: Existing compounds or prior art that disclose similar structures.
• Obviousness: If modifications are seen as routine or predictable.
• Claim Breadth: Overly broad claims may be vulnerable; narrower claims based on specific structural features tend to be more defensible.

---

Patent Landscape & Competitive Environment

Malaysian Patent Climate for Pharmaceuticals

Malaysia’s patent laws align with TRIPS (Trade-Related Aspects of Intellectual Property Rights) standards, emphasizing patent protection for inventions that are novel, inventive, and industrially applicable. The local patent landscape features:

• Emerging R&D: Growing investments in biotech and pharmaceuticals.
• Patent Filing Trends: Rising filings in chemical and biological inventions, especially by multinational corporations and local biotech firms.
• Patent Challenges: The Malaysian patent examiners rigorously scrutinize novelty and inventive step, often requiring detailed disclosures.

Key Competitors & Patent Holders

While the specific assignee of MY142499 is undisclosed here, similar patents are held by:

• Global pharma companies with established portfolios in Southeast Asia.
• Local biotech entities seeking incremental innovations or niche therapies.
• Generic manufacturers, typically interested in formulations or methods that bypass patent barriers.

Patent Lifecycle & Supplementary Protection

Malaysia offers up to 20 years of patent protection. Innovators often seek supplementary protection certificates (SPCs) or data exclusivity periods to extend market viability, particularly important amidst the generic-drug proliferation.

---

Legal & Commercial Implications

Infringement Risks & Defensive Strategies

Patent protection enables licensors to prevent unauthorized manufacturing or use. For patent MY142499:

• Infringement would occur if a competitor produces or markets a compound or formulation falling within the scope of the claims.
• Defendants suspected of infringement might defend using validity arguments such as prior art or non-obviousness.

Strategic Patent Filing & Portfolio Management

Innovators should consider:

• Filing divisional or continuation applications to extend protection.
• Conducting frequent landscape analyses to identify competitors’ patents.
• Employing patent term extensions or complementary IP rights like trademarks for branding.

---

Key Takeaways

• Claim Specificity: The strength of MY142499 hinges on detailed, defensible claims that cover the inventive aspects, such as unique chemical modifications or therapeutic methods.
• Landscape Positioning: As Malaysia’s pharma IP landscape matures, patent teams must navigate local and regional patent laws, balancing broad protection with enforceability.
• Innovation Strategy: Continuous innovation, complemented by diligent patent drafting and landscape analysis, remains essential in maintaining competitive advantages.
• Legal Vigilance: Regular patentability searches and freedom-to-operate analyses mitigate infringement risks and inform licensing or litigation strategies.
• Market Impact: Patent protection facilitates commercialization, attract investment, and supports healthcare access through proprietary formulations or therapies.

---

Frequently Asked Questions (FAQs)

1. What is the typical scope of pharmaceutical patents like MY142499 in Malaysia?
Pharmaceutical patents commonly protect novel chemical compounds, their methods of synthesis, therapeutic uses, and formulations, with scope defined by specific structural and functional features.

2. How can patent claims be challenged or invalidated in Malaysia?
Challenges include prior art disclosures, obviousness, or insufficient disclosure. Validity proceedings occur before MyIPO, often based on oppositions or legal disputes.

3. How does Malaysia's patent law influence drug patenting strategies?
Malaysia’s TRIPS-compliant system encourages detailed disclosures and specific claims, prompting applicants to tailor claims narrowly to withstand legal scrutiny and maximize enforceability.

4. What are the implications for generic companies regarding patents like MY142499?
Generics may seek to develop design-around strategies or wait for patent expiration, unless they establish non-infringement through different formulations or manufacturing processes.

5. How does patent landscape analysis support pharmaceutical innovation in Malaysia?
It helps identify innovation gaps, monitor competitors’ filings, and inform patent filing strategies to ensure robust IP protection aligned with local market and regulatory trends.

---

Concluding Remarks

Patent MY142499 exemplifies the nuanced landscape of Malaysian pharmaceutical IP, where claim precision, strategic portfolio management, and regulatory adherence underpin commercial success. Stakeholders must leverage detailed patent landscape insights to foster innovation, protect R&D investments, and sustain competitive advantage in Malaysia’s evolving pharmaceutical sector.

---

References

Last updated: September 22, 2025

1. MyIPO Patent Database. https://www.myipo.gov.my
2. World Trade Organization. Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS).
3. Malaysian Patent Act 1983 (Amended).
4. Pharmaceutical Patent Trends in Southeast Asia, IP Department Reports.
5. Patentability Examination Guidelines, MyIPO.